AVP-21D9 + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Anthrax
Conditions
Anthrax
Trial Timeline
Aug 1, 2010 → Jun 1, 2011
NCT ID
NCT01202695About AVP-21D9 + Placebo
AVP-21D9 + Placebo is a phase 1 stage product being developed by Emergent BioSolutions for Anthrax. The current trial status is completed. This product is registered under clinical trial identifier NCT01202695. Target conditions include Anthrax.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01202695 | Phase 1 | Completed |
Competing Products
15 competing products in Anthrax